Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 2/2021

Open Access 01-02-2021 | Nitrate | Review

The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region

Authors: Kevin Cheng, Khaldoon Alhumood, Fayez El Shaer, Ranil De Silva

Published in: Advances in Therapy | Issue 2/2021

Login to get access

Abstract

Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.
Literature
1.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019:ehz425.
2.
Kligfield P. The early pathophysiolic understanding of angina pectoris (Edward Jenner, Caleb Hillier Parry, Alan Burns). Am J Cardiol. 1982;50(6):1433–5.PubMedCrossRef
3.
4.
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.PubMedPubMedCentralCrossRef
5.
Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Ngu Blackett K, et al. World Health Organization definition of myocardial infarction: 2008–09 revision. Int J Epidemiol. 2011;40(1):139–46.PubMedCrossRef
6.
Al-Nozha MM, Arafah MR, Al-Mazrou YY, Al-Maatouq MA, Khan NB, Khalil MZ, et al. Coronary artery disease in Saudi Arabia. Saudi Med J. 2004;25(9):1165–71.PubMed
7.
8.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.PubMedCrossRef
9.
Aljefree N, Ahmed F. Prevalence of cardiovascular disease and associated risk factors among adult population in the gulf region: a systematic review. Adv Public Health. 2015:235101.
10.
Motlagh B, O’Donnell M, Yusuf S. Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16(3):268–80.PubMedCrossRef
11.
12.
Dugani SB, Murad W, Damilig K, Atos J, Mohamed E, Callachan E, et al. Premature myocardial infarction in the Middle East and North Africa: rationale for the Gulf PREVENT Study. Angiology. 2019:3319719849737.
13.
Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. ehz660.
14.
Osman AM, Alsultan MS, Al-Mutairi MA. The burden of ischemic heart disease at a major cardiac center in Central Saudi Arabia. Saudi Med J. 2011;32(12):1279–84.PubMed
15.
Al Slamah T, Nicholl BI, Alslail FY, Melville CA. Self-management of type 2 diabetes in gulf cooperation council countries: a systematic review. PLoS ONE. 2017;12(12):e0189160.PubMedPubMedCentralCrossRef
16.
17.
18.
Al-Rubeaan K, Al-Manaa HA, Khoja TA, Ahmad NA, Al-Sharqawi AH, Siddiqui K, et al. Epidemiology of abnormal glucose metabolism in a country facing its epidemic: SAUDI-DM study. J Diabetes. 2015;7(5):622–32.PubMedCrossRef
19.
Omar MS, Khudada K, Safarini S, Mehanna S, Nafach J. DiabCare survey of diabetes management and complications in the Gulf countries. Indian J Endocrinol Metab. 2016;20(2):219–27.PubMedPubMedCentralCrossRef
20.
Shehab A, Bhagavathula AS, Al-Rasadi K, Alshamsi F, Al Kaab J, Thani KB, et al. Diabetes and mortality in acute coronary syndrome: findings from the Gulf COAST registry. Curr Vasc Pharmacol. 2018.
21.
Duarte R, Castela S, Reis RP, Correia MJ, Ramos A, Pereira AP, et al. Acute coronary syndrome in a diabetic population—risk factors and clinical and angiographic characteristics. Rev Port Cardiol. 2003;22(9):1077–88.PubMed
22.
Herlitz J, Brandrup-Wognsen G, Emanuelsson H, Haglid M, Karlson BW, Karlsson T, et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care. 1996;19(7):698–703.PubMedCrossRef
23.
Peterson PN, Spertus JA, Magid DJ, Masoudi FA, Reid K, Hamman RF, et al. The impact of diabetes on one-year health status outcomes following acute coronary syndromes. BMC Cardiovasc Disord. 2006;6:41.PubMedPubMedCentralCrossRef
24.
Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, et al. A ‘diamond’ approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15:120–32.PubMedCrossRef
25.
Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, et al. β-Blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399–407.PubMedPubMedCentralCrossRef
26.
Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018;104(4):284–92.PubMed
27.
28.
Ferrari R, Pavasini R, Censi S, Squeri A, Rosano G. The new ESC guidelines for the diagnosis and management of chronic coronary syndromes: the good and the not so good. Curr Probl Cardiol. 2020:100554.
29.
Ferrari R, Rosano G. "2019 Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes": congratulations and tribulations. Eur Heart J Cardiovasc Pharmacother. 2020.
30.
Ambrosio G, Mugelli A, Lopez-Sendon J, Tamargo J, Camm J. Management of stable angina: a commentary on the European Society of Cardiology guidelines. Eur J Prev Cardiol. 2016;23(13):1401–12.PubMedCrossRef
31.
Manolis AJ, Poulimenos LE, Ambrosio G, Kallistratos MS, Lopez-Sendon J, Dechend R, et al. Medical treatment of stable angina: a tailored therapeutic approach. Int J Cardiol. 2016;220:445–53.PubMedCrossRef
32.
Iona Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359(9314):1269–75.CrossRef
33.
Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al. Stratified medical therapy using invasive coronary function testing in angina. The CorMicA Trial. 2018;72(23 Part A):2841–55.
34.
Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9.PubMedCrossRef
35.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–9.PubMedCrossRef
36.
Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–16.
37.
Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, Mejia Dolores JW, Rey Rodriguez DE, Loza Munarriz C. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev. 2017;2:CD011747.
38.
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–83.PubMedCrossRef
39.
Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(7):837–48.PubMedCrossRef
40.
Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281(20):1927–36.PubMedCrossRef
41.
Tarkin JM, Kaski JC. Nicorandil and long-acting nitrates: vasodilator therapies for the management of chronic stable angina pectoris. Eur Cardiol. 2018;13(1):23–8.PubMedPubMedCentralCrossRef
42.
Knorr M, Hausding M, Kröller-Schuhmacher S, Steven S, Oelze M, Heeren T, et al. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and s-glutathionylation of endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2011;31(10):2223–31.PubMedCrossRef
43.
Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol. 2007;49(12):1289–95.PubMedCrossRef
44.
Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol. 2001;37(2):505–9.PubMedCrossRef
45.
Caramori PR, Adelman AG, Azevedo ER, Newton GE, Parker AB, Parker JD. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol. 1998;32(7):1969–74.PubMedCrossRef
46.
Münzel T, Mollnau H, Hartmann M, Geiger C, Oelze M, Warnholtz A, et al. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol. 2000;36(2):626–34.CrossRef
47.
Munzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011;123(19):2132–44.PubMedCrossRef
48.
Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata N, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J. 1996;60(10):779–88.PubMedCrossRef
49.
Kim CH, Park TK, Cho SW, Oh MS, Lee DH, Seong CS, et al. Impact of different nitrate therapies on long-term clinical outcomes of patients with vasospastic angina: a propensity score-matched analysis. Int J Cardiol. 2018;252:1–5.PubMedCrossRef
50.
Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138(3):577–85.PubMedCrossRef
51.
Takahashi J, Nihei T, Takagi Y, Miyata S, Odaka Y, Tsunoda R, et al. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. Eur Heart J. 2015;36(4):228–37.PubMedCrossRef
52.
53.
Hirohata A, Yamamoto K, Hirose E, Kobayashi Y, Takafuji H, Sano F, et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study. EuroIntervention. 2014;9(9):1050–6.PubMedCrossRef
54.
Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, et al. Effects of the antianginal drugs ranolazine, nicorandil, and ivabradine on coronary microvascular function in patients with nonobstructive coronary artery disease: a meta-analysis of randomized controlled trials. Clin Ther. 2019.
55.
Herman AG, Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J. 2005;26(19):1945–55.PubMedCrossRef
56.
European Medicines Agency. Questions and answers on Ikorel, Dancor and associated names (nicorandil, 10 and 20 mg tablets). Outcome of a procedure under Article 30 of Directive 2001/83/EC. 2015.
57.
Kukovetz WR, Holzmann S, Poch G. Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S1–7.PubMedCrossRef
58.
Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013(9):CD005508.
59.
Sakai K, Shiraki Y, Nabata H. Cardiovascular effects of a new coronary vasodilator N-(2-hydroxyethyl)nicotinamide nitrate (SG-75): comparison with nitroglycerin and diltiazem. J Cardiovasc Pharmacol. 1981;3(1):139–50.PubMedCrossRef
60.
Suryapranata H, Serruys PW, De Feyter PJ, Verdouw PD, Hugenholtz PG. Coronary vasodilatory action after a single dose of nicorandil. Am J Cardiol. 1988;61(4):292–7.PubMedCrossRef
61.
Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S93-102.PubMed
62.
Matsubara T, Minatoguchi S, Matsuo H, Hayakawa K, Segawa T, Matsuno Y, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol. 2000;35(2):345–51.PubMedCrossRef
63.
Sato T, Sasaki N, O’Rourke B, Marban E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol. 2000;35(2):514–8.PubMedCrossRef
64.
Cavero I, Djellas Y, Guillon JM. Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels. Cardiovasc Drugs Ther. 1995;9(Suppl 2):245–55.PubMedCrossRef
65.
Markham A, Plosker GL, Goa KL. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs. 2000;60(4):955–74.PubMedCrossRef
66.
Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res. 2002;55(3):534–43.PubMedCrossRef
67.
Szewczyk A, Marban E. Mitochondria: a new target for K channel openers? Trends Pharmacol Sci. 1999;20(4):157–61.PubMedCrossRef
68.
He W, Su Q, Liang J, Sun Y, Wang X, Li L. The protective effect of nicorandil on cardiomyocyte apoptosis after coronary microembolization by activating Nrf2/HO-1 signaling pathway in rats. Biochem Biophys Res Commun. 2018;496(4):1296–301.PubMedCrossRef
69.
Wu H, Ye M, Yang J, Ding J, Yang J, Dong W, et al. Nicorandil protects the heart from ischemia/reperfusion injury by attenuating endoplasmic reticulum response-induced apoptosis through PI3K/Akt signaling pathway. Cell Physiol Biochem. 2015;35(6):2320–32.PubMedCrossRef
70.
Izumiya Y, Kojima S, Kojima S, Araki S, Usuku H, Matsubara J, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis. 2011;214(2):415–21.PubMedCrossRef
71.
Jaraki O, Strauss WE, Francis S, Loscalzo J, Stamler JS. Antiplatelet effects of a novel antianginal agent, nicorandil. J Cardiovasc Pharmacol. 1994;23(1):24–30.PubMedCrossRef
72.
Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol. 2005;46(1):63–7.PubMedCrossRef
73.
Frydman A. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S34–44.PubMedCrossRef
74.
Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ, Bouthier J, et al. Pharmacokinetics of nicorandil. Am J Cardiol. 1989;63(21):25J–33J.PubMedCrossRef
75.
Molinaro M, Villa G, Regazzi MB, Salvadeo A, Segagni S, Rondanelli R, et al. Pharmacokinetics of nicorandil in patients with normal and impaired renal function. Eur J Clin Pharmacol. 1992;42(2):203–7.PubMedCrossRef
76.
Wagner G. Selected issues from an overview on nicorandil: tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S86–92.PubMedCrossRef
77.
Kool MJ, Spek JJ, Struyker Boudier HA, Hoeks AP, Reneman RS, van Herwaarden RH, et al. Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers. Cardiovasc Drugs Ther. 1995;9(2):331–7.PubMedCrossRef
78.
Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol. 1989;63(21):61J-65J.PubMedCrossRef
79.
Hayata N, Araki H, Nakamura M. Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study. Am Heart J. 1986;112(6):1245–50.PubMedCrossRef
80.
Kinoshita M, Nishikawa S, Sawamura M, Yamaguchi S, Mitsunami K, Itoh M, et al. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. Am J Cardiol. 1986;58(9):733–8.PubMedCrossRef
81.
Meany TB, Richardson P, Camm AJ, Coltart J, Griffith M, Maltz MB, et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol. 1989;63(21):66J-70J.PubMedCrossRef
82.
Ciampricotti R, Schotborgh C, de Kam PJ, van Herwaarden R. A comparison of nicorandil with isosorbide mononitrate in elderly patients with stable coronary heart disease: the SNAPE study. Am Heart J. 2000;139:e1–9.CrossRef
83.
Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S74–81.PubMedCrossRef
84.
Lai C, Onnis E, Solinas R, Orani E, Lai G, Cadeddu M, et al. A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononitrate. Cardiologia. 1991;36(9):703–11.PubMed
85.
Falcone C, Auguardro C. A double blind comparison of nicorandil and isosorbide dinitrate slow release in patients with stable angina pectoris [abstract]. Eur Heart J. 1993;14:376.
86.
Zhu WL, Shan YD, Guo JX, Wei JP, Yang XC, Li TD, et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J. 2007;71(6):826–33.PubMedCrossRef
87.
Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de Divitiis O, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther. 1993;7(1):119–23.PubMedCrossRef
88.
Hughes LO, Rose EL, Lahiri A, Raftery EB. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol. 1990;66(7):679–82.PubMedCrossRef
89.
Meeter K, Kelder JC, Tijssen JG, Bucx JJ, Henneman JA, Kerker JP, et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S59–66.PubMed
90.
Raftery EB, Lahiri A, Hughes LO, Rose EL. A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. Eur Heart J. 1993;14(Suppl B):35–9.PubMedCrossRef
91.
Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J. 1993;14(Suppl B):30–4.PubMedCrossRef
92.
Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2010;74(3):503–9.PubMedCrossRef
93.
SWAN Study Group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol. 1999;2:213–7.
94.
Ulvenstam G, Diderholm E, Frithz G, Gudbrandsson T, Hedback B, Hoglund C, et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S67–73.PubMedCrossRef
95.
Lesnefsky EJ. The IONA study: preparing the myocardium for ischaemia? Lancet. 2002;359(9314):1262–3.PubMedCrossRef
96.
97.
Walker A, McMurray J, Stewart S, Berger W, McMahon AD, Dargie H, et al. Economic evaluation of the impact of nicorandil in angina (IONA) trial. Heart. 2006;92(5):619–24.PubMedPubMedCentralCrossRef
98.
Luo B, Wu P, Bu T, Zeng Z, Lu D. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and meta-analysis of the literature. Int J Cardiol. 2014;176(3):661–9.PubMedCrossRef
99.
Jiang J, Li Y, Zhou Y, Li X, Li H, Tang B, et al. Oral nicorandil reduces ischemic attacks in patients with stable angina: a prospective, multicenter, open-label, randomized, controlled study. Int J Cardiol. 2016;224:183–7.PubMedCrossRef
100.
Kishida H, Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris. Clin Pharmacol Ther. 1987;42(2):166–74.PubMedCrossRef
101.
Picard F, Sayah N, Spagnoli V, Adjedj J, Varenne O. Vasospastic angina: a literature review of current evidence. Arch Cardiovasc Dis. 2019;112(1):44–55.PubMedCrossRef
102.
Chen JW, Lee WL, Hsu NW, Lin SJ, Ting CT, Wang SP, et al. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol. 1997;80(1):32–8.PubMedCrossRef
103.
Ito N, Nanto S, Doya Y, Kurozumi Y, Natsukawa T, Shibata H, et al. Beneficial effects of intracoronary nicorandil on microvascular dysfunction after primary percutaneous coronary intervention: demonstration of its superiority to nitroglycerin in a cross-over study. Cardiovasc Drugs Ther. 2013;27(4):279–87.PubMedCrossRef
104.
Russo G, Di Franco A, Lamendola P, Tarzia P, Nerla R, Stazi A, et al. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther. 2013;27(3):229–34.PubMedCrossRef
105.
Jia Q, Shi S, Yuan G, Shi J, Shi S, Wei Y, et al. The effect of nicorandil in patients with cardiac syndrome X: a meta-analysis of randomized controlled trials. Medicine. 2020;99(37):e22167.PubMedPubMedCentralCrossRef
106.
Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Delayed recovery of coronary resistive vessel function after coronary angioplasty. J Am Coll Cardiol. 1993;21(3):612–21.PubMedCrossRef
107.
Crea F, Bairey Merz CN, Beltrame JF, Berry C, Camici PG, Kaski JC, et al. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 2019;40(29):2455–62.PubMedCrossRef
108.
Ferrari R, Ford I, Fox K, Challeton JP, Correges A, Tendera M, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396(10254):830–8.PubMedCrossRef
109.
Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10014):136–45.PubMedCrossRef
110.
Ye Z, Su Q, Li L. The clinical effect of nicorandil on perioperative myocardial protection in patients undergoing elective PCI: a systematic review and meta-analysis. Sci Rep. 2017;7:45117.PubMedPubMedCentralCrossRef
111.
Zhao XT, Zhang CF, Liu QJ. Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention. BMC Cardiovasc Disord. 2019;19(1):144.PubMedPubMedCentralCrossRef
112.
Sara JD, Taher R, Kolluri N, Vella A, Lerman LO, Lerman A. Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease. Cardiovasc Diabetol. 2019;18(1):22.PubMedPubMedCentralCrossRef
113.
Impact of nicorandil in angina: subgroup analyses. Heart. 2004;90(12):1427–30.
114.
Sakai K, Kuromaru O. Nitrate tolerance: comparison of nicorandil, isosorbide dinitrate, and nitroglycerin in anesthetized dogs. J Cardiovasc Pharmacol. 1987;10(Suppl 8):S17–24.PubMedCrossRef
115.
Henry PJ, Horowitz JD, Louis WJ. Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J Cardiovasc Pharmacol. 1990;15(3):365–70.PubMedCrossRef
116.
Rajaratnam R, Brieger DB, Hawkins R, Freedman SB. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol. 1999;83(7):1120–4, a9.PubMedCrossRef
117.
Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33(3):654–60.PubMedCrossRef
118.
Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Shimizu M, Nishii T, et al. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol. 2001;37(3):719–25.PubMedCrossRef
119.
Li Y, Liu Y, Peng W, Wang B, Geng T, Xu Z. Therapeutic effect and safety of nicorandil in treatment of refractory angina pectoris. Int J Clin Exp Med. 2018;11(7):6993–8.
120.
Zeng L, Chen X, Wen Y, Chun L. Clinical study of isosorbide mononitrate combined with nicorandil in treatment of type 2 diabetic patients with stable angina pectoris. World Phytomedicines. 2016;1:54–8.
121.
Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation. 2014;130(19):1749–67.PubMedCrossRef
Metadata
Title
The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region
Authors
Kevin Cheng
Khaldoon Alhumood
Fayez El Shaer
Ranil De Silva
Publication date
01-02-2021
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 2/2021
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01582-w

Other articles of this Issue 2/2021

Advances in Therapy 2/2021 Go to the issue

Original Research

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study

Original Research

Vardenafil in the Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis

Original Research

Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion

Original Research

Therapeutic Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women with Cervical Uterine High-Risk HPV Infection: A Retrospective Observational Study

Review

Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review

Original Research

The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits